Factor XI deficiency - from molecular genetics to clinical management

被引:45
作者
O'Connell, NM
机构
[1] Royal Free Hampstead NHS Trust, Katharine Dormandy Haemophilia Ctr, London NW3 2QG, England
[2] Royal Free Hampstead NHS Trust, Haemostasis Unit, London NW3 2QG, England
关键词
factor XI deficiency; molecular genetics; genotype; mutations; recombinant factor VIIa;
D O I
10.1097/00001721-200306001-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor XI (FXI) deficiency is a rare bleeding disorder, but is known to occur more frequently in a number of well-defined populations. FXI deficiency is most notable for its variable clinical phenotype. The FXI gene is located at the distal end of the long arm of chromosome 4 and encodes a 607 amino acid mature protein, which is a zymogen for a serine protease. Although the serine protease domain is similar to that of many other coagulation factors, the heavy chain differs in that it contains four tandem Apple domains. FXI is also unique in that it exists as a homodimer, with this dimerization appearing essential for normal function. A total of 39 different FXI mutations have been identified to date, affecting both the catalytic and Apple domains. This article will review the molecular genetics of FXI deficiency with particular focus on the implications of these findings for the clinical management of this condition. The potential utility of alternatives to plasma-derived FXI concentrate, such as recombinant factor Vila (rFVIIa, NovoSeven(R)) will also be explored. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:S59 / S64
页数:6
相关论文
共 30 条
[1]   FACTOR-XI DEFICIENCY IN ASHKENAZI JEWS IN ISRAEL [J].
ASAKAI, R ;
CHUNG, DW ;
DAVIE, EW ;
SELIGSOHN, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :153-158
[2]  
ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7721
[3]   IDENTIFICATION AND CHARACTERIZATION OF A BINDING-SITE FOR PLATELETS IN THE APPLE-3 DOMAIN OF COAGULATION-FACTOR-XI [J].
BAGLIA, FA ;
JAMESON, BA ;
WALSH, PN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (12) :6734-6740
[4]   The use of recombinant factor VIIa (NovoSeven®) in a patient with a factor XI deficiency and a circulating anticoagulant [J].
Billon, S ;
Le Niger, C ;
Escoffre-Barbe, M ;
Vicariot, M ;
Abgrall, JF .
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (07) :551-553
[5]  
BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P194
[6]  
BOUMA BN, 1977, J BIOL CHEM, V252, P6432
[7]   HUMAN-PLASMA PREKALLIKREIN, A ZYMOGEN TO A SERINE PROTEASE THAT CONTAINS 4 TANDEM REPEATS [J].
CHUNG, DW ;
FUJIKAWA, K ;
MCMULLEN, BA ;
DAVIE, EW .
BIOCHEMISTRY, 1986, 25 (09) :2410-2417
[8]   AMINO-ACID-SEQUENCE OF HUMAN FACTOR-XI, A BLOOD-COAGULATION FACTOR WITH 4 TANDEM REPEATS THAT ARE HIGHLY HOMOLOGOUS WITH PLASMA PREKALLIKREIN [J].
FUJIKAWA, K ;
CHUNG, DW ;
HENDRICKSON, LE ;
DAVIE, EW .
BIOCHEMISTRY, 1986, 25 (09) :2417-2424
[9]   Model for a factor IX activation complex on blood platelets: dimeric conformation of factor IXa is essential [J].
Gailani, D ;
Ho, D ;
Sun, MF ;
Cheng, QF ;
Walsh, PN .
BLOOD, 2001, 97 (10) :3117-3122
[10]  
Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009